Approved Pfizer breast cancer drug impresses in latest study

April 15, 2015 5:15 PM

7 0

Approved Pfizer breast cancer drug impresses in latest study

(Reuters) - Pfizer Inc said on Wednesday the first formal late-stage trial of its approved treatment for advanced breast cancer, Ibrance, was stopped early after the medicine met its goal of delaying progression of the disease in previously treated patients.

J.P.Morgan analyst Chris Schott said in a research note that the successful trial results should boost demand for the recently approved treatment, which works differently than approved medicines and has blockbuster sales potential. Some analysts have predicted the drug could eventually generate annu...

Also read: Synergy Pharma's irritable bowel drug succeeds in key study

Read more

To category page

Loading...